Phase I Trial of Elactocin
Author Information
Author(s): ES Newlands, GJS Rustin, MH Brampton
Primary Institution: Department of Medical Oncology, Charing Cross Hospital
Hypothesis
Elactocin is a novel anti-tumour antibiotic that may have significant activity against various cancers.
Conclusion
Elactocin has a unique toxicity profile with marked malaise and anorexia, and no effective dosing schedule was found to recommend for further trials.
Supporting Evidence
- Elactocin was administered to 33 patients with advanced refractory cancer.
- Profound anorexia and malaise were identified as dose-limiting toxicities.
- No partial or complete responses were observed in the trial.
Takeaway
Elactocin is a new cancer drug that made patients feel very sick, so doctors decided not to use it anymore.
Methodology
Patients with advanced refractory cancer were treated with elactocin in various infusion schedules to determine toxicity and maximum tolerated dose.
Limitations
No pharmacology was performed due to interference from other substances in patient samples.
Participant Demographics
19 males and 14 females with a median age of 49 years.
Want to read the original?
Access the complete publication on the publisher's website